A5102804648- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Occupational and environmental lung diseases
- Neuroblastoma Research and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Colorectal Cancer Treatments and Studies
- T-cell and B-cell Immunology
- Advanced Radiotherapy Techniques
- Pulmonary Hypertension Research and Treatments
- Medical Imaging Techniques and Applications
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Esophageal Cancer Research and Treatment
- Pneumonia and Respiratory Infections
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Virus-based gene therapy research
- Peptidase Inhibition and Analysis
- Microbial infections and disease research
- Gastric Cancer Management and Outcomes
Xencor (United States)
2020-2024
Central South University
2024
Soochow University
2023
Shanghai Sixth People's Hospital
2010-2012
First Affiliated Hospital of Guangdong Pharmaceutical University
2010
Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is attractive target tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells kill CD123+ tumor cells. This phase 1 study's primary objectives were safety tolerability identification of maximum tolerated dose/recommended dose...
<h3>Background</h3> XmAb20717 is a humanized bispecific monoclonal antibody that simultaneously targets PD-1 and CTLA-4. We report updated data on patients treated at the recommended expansion dose from an ongoing, multicenter, Phase 1, dose-escalation -expansion study of intravenous in with selected advanced solid tumors progressed after treatment all standard therapies or no therapeutic options. <h3>Methods</h3> A maximum tolerated was not reached escalation. 10 mg/kg every 2 weeks (Q2W)...
Pulmonary fibrosis is a chronic progressive disease with complex pathogenesis, short median survival time, and high mortality. There are few effective drugs approved for pulmonary treatment. This study aimed to evaluate the effect of praziquantel (PZQ) on bleomycin (BLM)-induced fibrosis.
This study aimed to investigate the clinical significance of serum microRNA-146a and pro-inflammatory factors in children with Mycoplasma pneumoniae pneumonia after azithromycin treatment. is known regulate inflammatory responses, excessive inflammation a primary characteristic MPP. Children MPP received conventional symptomatic therapy along intravenous administration for one week. Serum levels were measured using RT-qPCR ELISA kits, respectively. The correlation between was analyzed by...
e15001 Background: Interim safety and PD data from an ongoing first-in-human, multi-center, open-label dose escalation study of XmAb20717 (XmAb20717-01; NCT03517488) are reported here. The primary objectives were to determine safety, tolerability, the MTD and/or recommended doses (RDs). Secondary included preliminary anti-tumor activity PK/PD. Methods: A 3+3 design was used establish MTD/RD(s) for infusions on Days 1 15 each 28-day cycle. DLT evaluation based Cycle through Day 28. Patients...
<h3>Background</h3> XmAb20717 is a humanized bispecific monoclonal antibody that simultaneously targets PD-1 and CTLA-4. We report preliminary data from an ongoing, multicenter, Phase 1 study investigating the safety/tolerability, pharmacokinetics/pharmacodynamics, clinical activity (RECIST 1.1) of in patients with selected advanced solid tumors. <h3>Methods</h3> A 3+3 dose-escalation design was used to establish maximum tolerated (MTD)/recommended dose for evaluation parallel expansion...
<h3>Background</h3> Interleukin 2 (IL-2) signaling is essential for the development, survival, and suppressive function of T regulatory cells (Tregs). Diminished IL-2 Treg functional impairment are associated with autoimmune diseases, including systemic lupus erythematosus (SLE)<sup>[1]-[3]</sup>. XmAb564 a potency reduced, monomeric human heterodimeric Fc-fusion protein extended half-life increased binding affinity receptor alpha (CD25) to selectively expand Tregs, being developed treatment...
Objective To investigate the patterns of change in thyroid functional parameters ( serum TSH,FT3, and FT4 ) patients with papillary cancer (PTC) before after initial 131I treatment for thyroidal remnant ablation. Methods Seventy-four PTC patients, treated 3.7 GBq 131 I therapy, were divided into two groups, group A TSH＜30 mIU/L B TSH ≥30 day treatment. Five days treatment, re-examined FT3, FT4, levels.Results In (22 cases), 5 ablation FT4significantly increased by 88% FT3 87%, while...
Objective To investigate the short-term effect on parathyroid function after 131I treatment for DTC.Methods Seventy-three patients ( 15 males,58 females,mean age (44.59 ± 12.89) y) who underwent thyroid remnant ablation were enrolled in study.Serum PTH and Ca2+levels evaluated at baseline 5 d administration.PTH levels compared based gender,age residual mass.The t-test,analysis of variance x2 test used statistical analysis.Results Fifty-eight showed decreased (79.45％),and 8 10.95％ ) below...